Role of Tolerability in Using Immunotherapy for Metastatic Melanoma
Source: Targeted Oncology, September 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, April K.S. Salama, MD, and other physicians discussed which patients are more challenging when it comes to tolerating dual immunotherapy as frontline therapy for metastatic melanoma. This is the second of 2 articles based on this event.
DISCUSSION QUESTIONS
Thinking about the preferred first-line regimens for patients with non–BRAF-mutated, unresectable/metastatic melanoma, what type of patient do consider ideal for each one?
For what types of patients are you “on the fence” about whether to use monotherapy or dual immunotherapy?
APRIL K.S. SALAMA, MD: I’m curious about others experiences; is anyone’s interested in sharing?